Diabetes Not a Major Driver of Oncologic Outcomes in Renal Cell Carcinoma
Researchers have questioned whether diabetes exerts adverse effects on the prognosis of RCC.
Renal Cell Carcinoma
Belzutifan Demonstrates Efficacy in VHL-Associated Renal Cell Carcinoma
Belzutifan demonstrated activity against both RCC and non-RCC neoplasms associated with VHL disease.
Can Quality of Life Assessments Predict PFS, OS Across Cancer Types?
Recent studies showed associations between quality of life scores and survival in lung and prostate cancer as well as renal cell carcinoma.
Radiation Therapy for Oligometastatic Renal Cell Carcinoma Promising
Serial radiation therapy could provide an alternative to standard-of-care systemic therapy.
Immune Checkpoint Inhibitors May Not Benefit Trial-Ineligible Cancer Patients
The restricted mean survival times were similar at 12 months and 36 months.
Adverse Radiologic and Pathologic Features Predict Worse Survival Outcomes in Small Renal Masses Following Nephrectomy
Researchers hypothesized that adverse radiologic and pathologic T3 features are predictive of worse outcomes in small renal masses.
Cytoreductive Nephrectomy Plus Active Surveillance Benefits Some With Metastatic Renal Cell Carcinoma
The median cancer-specific survival was 56.5 months.
First-Line Nivolumab Plus Ipilimumab May Offer Greater Cost Efficiency Than Pembrolizumab Plus Axitinib in Advanced Renal Cell Carcinoma
The monthly incremental cost per survivor relative to sunitinib for nivolumab plus ipilimumab decreased over time from $90,035 for 12 months to $18,881 for 48 months.
Predicting Long-Term Survival With Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma
Patients with smaller target lesions at baseline were more likely to be long-term survivors.
Oncologists Appear to Prefer IO/IO to IO/TKI Combinations in First-Line Metastatic Renal Cell Carcinoma
The investigators aimed to understand how oncologists decide between IO/IO and IO/TKI treatment options via survey.
- Loading...
Loading...
Next post in IKCS 2021
Loading... 
Loading...